missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human GPSM1 (aa 387-454) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (90%), Rat (90%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-59911 (PA5-59911. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
G-protein signaling modulators (GPSMs) play diverse functional roles through their interaction with G-protein subunits. This gene encodes a receptor-independent activator of G protein signaling, which is one of several factors that influence the basal activity of G-protein signaling systems. The protein contains seven tetratricopeptide repeats in its N-terminal half and four G-protein regulatory (GPR) motifs in its C-terminal half. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Specifications
Specifications
| Accession Number | Q86YR5 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 26086 |
| Name | Human GPSM1 (aa 387-454) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 1810037C22Rik; Activator of G-protein signaling 3; Ags3; AW107933; C10a; DKFZP727I051; G-protein signaling modulator 1; G-protein signaling modulator 1 (AGS3-like, C. elegans); G-protein signalling modulator 1 (AGS3-like, C. elegans); G-protein-signaling modulator 1; Gpsm1 |
| Common Name | GPSM1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction